Global Plasma Protease C1-inhibitor Treatment Market to Surpass US$ 10,603.4 Million by 2027, Says Coherent Market Insights (CMI)

Global Plasma Protease C1-inhibitor Treatment Market to Surpass US$ 10,603.4 Million by 2027, Says Coherent Market Insights (CMI)




Global Plasma Protease C1-inhibitor Treatment Market to Surpass US$ 10,603.4 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#Antagonist–According to Coherent Market Insights, the global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Plasma Protease C1-inhibitor Treatment Market:

Positive clinical trial results integrated with assured safety profiles to cater the unmet need of the HAE disease are the major factors, which is expected to augment the global hereditary angioedema market over the forecast period. For instance, in August 2018, Adverum Biotechnologies, Inc. a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ADVM-053, a preclinical gene therapy candidate being investigated as a potential single‑administration treatment for HAE, which has the potential to provide sustained levels of the C1 esterase inhibitor (“C1EI”) protein.

The increasing number of hereditary angioedema cases and the hereditary nature giving the disease an ability to pass the defective gene to the future generations are expected to propel market growth. For instance, according to the survey by International Hereditary Angioedema Organization (HAEi), 2015, the global prevalence of hereditary angioedema is estimated to be around 1 in 10,000 to 50,000 people, meaning that around a quarter million people suffer globally from this rare and life threatening deficiency condition.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4262

Moreover, increasing support from non-profit organizations towards intensive research is expected to accelerate the plasma protease C1-inhibitor treatment market. The organizations are focusing on increasing global HAE awareness by educating and empowering patient, providing access to suitable therapy/treatment. The organizations are also working towards intensive research to find a cure. For instance, a non-profit organization named HAEi is dedicated towards spreading awareness of C1-inhibitor deficiencies and to improve diagnosis, facilitating access to reimbursement of the HAE therapies, enabling lifelong health for the global patients.

Key Market Takeaways:

The global plasma protease C1-inhibitor treatment market is expected to exhibit a CAGR of 18.2% during the forecast period, owing to increasing prevalence of hereditary angioedema. For instance, according to the survey by International Hereditary Angioedema Organization (HAEi), 2015, the global prevalence of hereditary angioedema is estimated to be around 1 in 10,000 to 50,000 people, meaning that around a quarter million people suffer globally from this rare and life threatening deficiency condition.

Among drug type, C1-inhibitor segment is expected to hold a dominant position in the plasma protease C1-inhibitor treatment market, owing to the robust number of drugs approved by the regulatory agencies. For instance, in June 2017, CSL Behring, a global biopharmaceutical company, received the U.S. Food and Drug Administration for HAEGARDA (C1 Esterase Inhibitor Subcutaneous (Human)).

Competitive Landscape:

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4262

Market Segmentation:

  • Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type:

    • C1-inhibitors
    • Kallikrein Inhibitor
    • Selective Bradykinin B2 Receptor Antagonist
  • Global Plasma Protease C1-inhibitor Treatment Market, By Dosage:

    • Lyophilized
    • Injectable
  • Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel:

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Plasma Protease C1-inhibitor Treatment Market, By Region:

    • North America

      • By Country:

        • U.S.
        • Canada
    • Latin America

      • By Country:

        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe

      • By Country:

        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific

      • By Country:

        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East

      • By Country/Region:

        • GCC
        • Israel
        • Rest of Middle East
    • Africa

      • By Country/Region:

        • South Africa
        • Central Africa
        • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter